Zhejiang Ausun Pharmaceutical Co., Ltd.

Informe acción SHSE:603229

Capitalización de mercado: CN¥7.0b

Zhejiang Ausun Pharmaceutical Crecimiento futuro

Future controles de criterios 3/6

Zhejiang Ausun Pharmaceutical is forecast to grow earnings and revenue by 20.4% and 17.5% per annum respectively. EPS is expected to grow by 19.8% per annum. Return on equity is forecast to be 13.9% in 3 years.

Información clave

20.4%

Tasa de crecimiento de los beneficios

19.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals19.3%
Tasa de crecimiento de los ingresos17.5%
Rentabilidad financiera futura13.9%
Cobertura de analistas

Low

Última actualización25 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise

Oct 08
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise

Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet

Jul 31
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet

Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified

Mar 06
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified

Previsiones de crecimiento de beneficios e ingresos

SHSE:603229 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20261,2494173785151
12/31/20251,0523452153861
12/31/20249072931143261
9/30/2024835258135295N/A
6/30/202484027452220N/A
3/31/202480025070196N/A
12/31/202381725458222N/A
9/30/2023858284-6618N/A
6/30/202385227314136N/A
3/31/2023822258-59168N/A
12/31/2022765235-151121N/A
9/30/2022718213-232113N/A
6/30/2022665186-29941N/A
3/31/2022631173-156173N/A
12/31/2021570146-137174N/A
9/30/2021537131-70221N/A
6/30/20214851175227N/A
3/31/2021474110-30120N/A
12/31/20204098746138N/A
9/30/20204067255104N/A
6/30/20203897860121N/A
3/31/2020329702680N/A
12/31/2019308563888N/A
9/30/2019293621178N/A
6/30/201925751-1443N/A
3/31/201925250-3829N/A
12/31/201824444-4412N/A
9/30/201825554-1346N/A
6/30/201826652N/A36N/A
3/31/201825143N/A41N/A
12/31/201724053N/A49N/A
9/30/201721755N/A43N/A
6/30/201721662N/A108N/A
3/31/201719758N/A114N/A
12/31/201619957N/A93N/A
3/31/201625962N/A41N/A
12/31/201526361N/A54N/A
12/31/201420122N/A21N/A
12/31/201312116N/A16N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 603229's forecast earnings growth (20.4% per year) is above the savings rate (2.9%).

Beneficios vs. Mercado: 603229's earnings (20.4% per year) are forecast to grow slower than the CN market (25.8% per year).

Beneficios de alto crecimiento: 603229's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: 603229's revenue (17.5% per year) is forecast to grow faster than the CN market (14% per year).

Ingresos de alto crecimiento: 603229's revenue (17.5% per year) is forecast to grow slower than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 603229's Return on Equity is forecast to be low in 3 years time (13.9%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y